These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effects of GH replacement on 24-h ambulatory blood pressure and its circadian rhythm in adult GH deficiency. Ahmad AM; Hopkins MT; Weston PJ; Fraser WD; Vora JP Clin Endocrinol (Oxf); 2002 Apr; 56(4):431-7. PubMed ID: 11966735 [TBL] [Abstract][Full Text] [Related]
4. Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly. Hernandez I; Soderlund D; Espinosa-de-los-Monteros AL; Ochoa R; Zarate A; Mercado M J Neurosurg; 1999 Apr; 90(4):647-50. PubMed ID: 10193608 [TBL] [Abstract][Full Text] [Related]
5. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Florimonte L; Salvatore M; Lombardi G J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056 [TBL] [Abstract][Full Text] [Related]
6. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Plöckinger U; Quabbe HJ Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331 [TBL] [Abstract][Full Text] [Related]
7. Effect of octreotide pretreatment on surgical outcome in acromegaly. Colao A; Ferone D; Cappabianca P; del Basso De Caro ML; Marzullo P; Monticelli A; Alfieri A; Merola B; Calì A; de Divitiis E; Lombardi G J Clin Endocrinol Metab; 1997 Oct; 82(10):3308-14. PubMed ID: 9329359 [TBL] [Abstract][Full Text] [Related]
8. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular consequences of early-onset growth hormone excess. Colao A; Spinelli L; Cuocolo A; Spiezia S; Pivonello R; di Somma C; Bonaduce D; Salvatore M; Lombardi G J Clin Endocrinol Metab; 2002 Jul; 87(7):3097-104. PubMed ID: 12107207 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295 [TBL] [Abstract][Full Text] [Related]
11. Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels. Lindsay JR; McConnell EM; Hunter SJ; McCance DR; Sheridan B; Atkinson AB Pituitary; 2004; 7(3):139-144. PubMed ID: 16328564 [TBL] [Abstract][Full Text] [Related]
12. Octreotide as primary therapy for acromegaly. Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397 [TBL] [Abstract][Full Text] [Related]
13. Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features. Terzolo M; Matrella C; Boccuzzi A; Luceri S; Borriero M; Reimondo G; Pia A; Rovero E; Paccotti P; Angeli A J Endocrinol Invest; 1999 Jan; 22(1):48-54. PubMed ID: 10090137 [TBL] [Abstract][Full Text] [Related]
14. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. Maison P; Tropeano AI; Macquin-Mavier I; Giustina A; Chanson P J Clin Endocrinol Metab; 2007 May; 92(5):1743-7. PubMed ID: 17311857 [TBL] [Abstract][Full Text] [Related]
15. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408 [TBL] [Abstract][Full Text] [Related]
16. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients. Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479 [TBL] [Abstract][Full Text] [Related]
17. Assessment of functional liver mass and plasma flow in acromegaly before and after long-term treatment with octreotide. Avagnina P; Martini M; Terzolo M; Sansoé G; Peretti P; Tinivella M; Pia A; Molino G; Angeli A Metabolism; 1996 Jan; 45(1):109-13. PubMed ID: 8544766 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798 [TBL] [Abstract][Full Text] [Related]
19. Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly. Biermasz NR; Pereira AM; Frölich M; Romijn JA; Veldhuis JD; Roelfsema F Am J Physiol Endocrinol Metab; 2004 Jan; 286(1):E25-30. PubMed ID: 14506078 [TBL] [Abstract][Full Text] [Related]
20. Effects of the peptide release inhibitor, octreotide, on daytime hypotension and on nocturnal hypertension in primary autonomic failure. Alam M; Smith G; Bleasdale-Barr K; Pavitt DV; Mathias CJ J Hypertens; 1995 Dec; 13(12 Pt 2):1664-9. PubMed ID: 8903629 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]